Copenhagen, DENMARK — Novo Nordisk defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss ...
Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...
CagriSema-treated patients achieved superior weight loss compared with those who received placebo. Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide 2.4mg and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback